Drugs / Trivalent influenza vaccine(B/V)
last change Sep 2021 re-read 2 minutes ago

Trivalent influenza vaccine(B/V)

Vaccine

Developed for
influenza

Trials 0

Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT04363359 Comparator Jan 2020 → Sep 2021 influenza Shanghai Institute Of Biological Products Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Trivalent influenza vaccine(B/V) ClinicalTrials.gov intervention name — accepted as the source's own label NCT04363359
Modality Vaccine “The inactivated split virion vaccines contained 7.5 μg of each hemagglutinin antigen of influenza A/H1N1, A/H3N2 and B/Victoria strains” NCT04363359